FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327718130> ?p ?o ?g. }

• W4327718130 endingPage "122096" @default.
• W4327718130 startingPage "122096" @default.
• W4327718130 abstract "Conventional chemotherapy for multiple myeloma (MM) faces the challenges of a low complete remission rate and transformation to recurrence/refractory. The current MM first-line clinical drug Bortezomib (BTZ) faces the problem of enhanced tolerance and nonnegligible side effects. B cell maturation antigen (BCMA), for its important engagement in tumor signaling pathways and novel therapy technologies such as Chimeric antigen receptor T-Cell immunotherapy (CAR-T) and Antibody Drug Conjugate (ADC), has been identified as an ideal target and attracted attention in anti-MM therapy. Emerging nanotechnology provided feasible methods for drug delivery and new therapeutic strategies such as photothermal therapy (PTT). Herein, we developed a BCMA-Targeting biomimetic photothermal nanomissile BTZ@BPQDs@EM @anti-BCMA (BBE@anti-BCMA) by integration of BTZ, black phosphorus quantum dots (BPQDs), Erythrocyte membrane (EM) and BCMA antibody (anti-BCMA). We hypothesized that this engineered nanomissile could attack tumor cells in triple ways and achieve effective treatment of MM. Consequently, the intrinsic biomimetic nature of EM and the active targeting property of anti-BCMA enhanced the accumulation of therapeutic agents in the tumor site. Besides, owing to the decrease in BCMA abundance, the potential apoptosis-inducing ability was revealed. With the support of BPQDs' photothermal effect, Cleaved-Caspase-3 and Bax signal increased significantly, and the expression of Bcl-2 was inhibited. Furthermore, the synergistic photothermal/chemo therapy can effectively inhibit tumor growth and reverse the disorder of NF-κB in vivo. Importantly, this biomimetic nanodrug delivery system and antibody induced synergistic therapeutic strategy efficiently killed MM cells with ignorable systemic toxicity, which is a promising method for the future anticancer treatment of hematological malignancies in clinics." @default.
• W4327718130 created "2023-03-18" @default.
• W4327718130 creator A5011419121 @default.
• W4327718130 creator A5019673494 @default.
• W4327718130 creator A5039253932 @default.
• W4327718130 creator A5040717619 @default.
• W4327718130 creator A5046858526 @default.
• W4327718130 creator A5053078091 @default.
• W4327718130 creator A5055212170 @default.
• W4327718130 creator A5056396619 @default.
• W4327718130 creator A5060504551 @default.
• W4327718130 creator A5065859286 @default.
• W4327718130 creator A5070903787 @default.
• W4327718130 creator A5072942966 @default.
• W4327718130 creator A5074421479 @default.
• W4327718130 creator A5078112505 @default.
• W4327718130 creator A5078622027 @default.
• W4327718130 creator A5081635779 @default.
• W4327718130 creator A5084518376 @default.
• W4327718130 creator A5086957292 @default.
• W4327718130 date "2023-06-01" @default.
• W4327718130 modified "2023-09-27" @default.
• W4327718130 title "Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo" @default.
• W4327718130 cites W1414886268 @default.
• W4327718130 cites W1565742957 @default.
• W4327718130 cites W1984437179 @default.
• W4327718130 cites W2013296669 @default.
• W4327718130 cites W2020794186 @default.
• W4327718130 cites W2070135451 @default.
• W4327718130 cites W2087824631 @default.
• W4327718130 cites W2124343538 @default.
• W4327718130 cites W2145479354 @default.
• W4327718130 cites W2165052205 @default.
• W4327718130 cites W2519415256 @default.
• W4327718130 cites W2586240677 @default.
• W4327718130 cites W2593295449 @default.
• W4327718130 cites W2731205692 @default.
• W4327718130 cites W2768895570 @default.
• W4327718130 cites W2788354946 @default.
• W4327718130 cites W2793738740 @default.
• W4327718130 cites W2794683780 @default.
• W4327718130 cites W2794885858 @default.
• W4327718130 cites W2885350532 @default.
• W4327718130 cites W2890781138 @default.
• W4327718130 cites W2894996603 @default.
• W4327718130 cites W2900464803 @default.
• W4327718130 cites W2913256870 @default.
• W4327718130 cites W2914322463 @default.
• W4327718130 cites W2915115434 @default.
• W4327718130 cites W2940447007 @default.
• W4327718130 cites W2940555664 @default.
• W4327718130 cites W2953877936 @default.
• W4327718130 cites W2955724393 @default.
• W4327718130 cites W2971706692 @default.
• W4327718130 cites W2971941127 @default.
• W4327718130 cites W2980945138 @default.
• W4327718130 cites W2982245165 @default.
• W4327718130 cites W3006004790 @default.
• W4327718130 cites W3006655689 @default.
• W4327718130 cites W3019437713 @default.
• W4327718130 cites W3028854163 @default.
• W4327718130 cites W3038604698 @default.
• W4327718130 cites W3043798055 @default.
• W4327718130 cites W3086762656 @default.
• W4327718130 cites W3086889801 @default.
• W4327718130 cites W3107475053 @default.
• W4327718130 cites W3115385053 @default.
• W4327718130 cites W3115993039 @default.
• W4327718130 cites W3139566881 @default.
• W4327718130 cites W3190058833 @default.
• W4327718130 cites W3200252815 @default.
• W4327718130 cites W4200388683 @default.
• W4327718130 cites W4210734847 @default.
• W4327718130 cites W4214661251 @default.
• W4327718130 cites W4285601651 @default.
• W4327718130 doi "https://doi.org/10.1016/j.biomaterials.2023.122096" @default.
• W4327718130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37075614" @default.
• W4327718130 hasPublicationYear "2023" @default.
• W4327718130 type Work @default.
• W4327718130 citedByCount "0" @default.
• W4327718130 crossrefType "journal-article" @default.
• W4327718130 hasAuthorship W4327718130A5011419121 @default.
• W4327718130 hasAuthorship W4327718130A5019673494 @default.
• W4327718130 hasAuthorship W4327718130A5039253932 @default.
• W4327718130 hasAuthorship W4327718130A5040717619 @default.
• W4327718130 hasAuthorship W4327718130A5046858526 @default.
• W4327718130 hasAuthorship W4327718130A5053078091 @default.
• W4327718130 hasAuthorship W4327718130A5055212170 @default.
• W4327718130 hasAuthorship W4327718130A5056396619 @default.
• W4327718130 hasAuthorship W4327718130A5060504551 @default.
• W4327718130 hasAuthorship W4327718130A5065859286 @default.
• W4327718130 hasAuthorship W4327718130A5070903787 @default.
• W4327718130 hasAuthorship W4327718130A5072942966 @default.
• W4327718130 hasAuthorship W4327718130A5074421479 @default.
• W4327718130 hasAuthorship W4327718130A5078112505 @default.
• W4327718130 hasAuthorship W4327718130A5078622027 @default.
• W4327718130 hasAuthorship W4327718130A5081635779 @default.
• W4327718130 hasAuthorship W4327718130A5084518376 @default.

• next